SCHEMBL954064

SCHEMBL954064

Cc1nc2ccc(Cl)nn2c1C(N)=S

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
TNF P01375 1/20 0.35
DYRK1A Q13627 6/20 0.34
DYRK2 Q92630 6/20 0.34
DYRK3 O43781 5/20 0.34
CCNA2 P20248 5/20 0.34
CDK2 P24941 5/20 0.34
CDK5 Q00535 5/20 0.34
CDK5R1 Q15078 5/20 0.34
DYRK1B Q9Y463 5/20 0.34
CCNT1 O60563 3/20 0.34
CDK9 P50750 3/20 0.34
KMT2A Q03164 4/20 0.33
MEN1 O00255 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL956476 0.84 ALDH1A1 (0.43) ALDH1A1KDM4ESMN1; SMN2POLBGAA
SCHEMBL6617429 0.79 ALDH1A1 (0.40) ALDH1A1KDM4ESMN1; SMN2POLBGAA
SCHEMBL12798307 0.74 KDM4E (0.47) ALDH1A1KDM4ESMN1; SMN2PRMT5WDR77
SCHEMBL953671 0.74 MAPK1 (0.52) ALDH1A1KDM4ESMN1; SMN2POLBGAA
SCHEMBL15562881 0.72 MEN1 (0.38) ALDH1A1KDM4ESMN1; SMN2POLBGAA
SCHEMBL477062 0.71 KDM4E (0.44) ALDH1A1KDM4ESMN1; SMN2PRMT5WDR77
SCHEMBL13122629 0.71 KDM4E (0.44) ALDH1A1KDM4ESMN1; SMN2PRMT5WDR77
SCHEMBL31001942 0.71 KDM4E (0.44) ALDH1A1KDM4ESMN1; SMN2PRMT5WDR77
SCHEMBL4052890 0.71 KDM4E (0.44) ALDH1A1KDM4ESMN1; SMN2PRMT5WDR77
SCHEMBL15690033 0.71 PDE10A (0.45) ALDH1A1KDM4ESMN1; SMN2POLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
EP-2398796-A1 HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE Merck Canada Inc. (CA) 2011-12-28 EP disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010094126-A1 HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2010-08-26 WO disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 ALDH1A1 1687/4885KDM4E 1981/4885SMN1; SMN2 3758/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 ALDH1A1 728/4885KDM4E 2304/4885SMN1; SMN2 3959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.